NEW YORK, June 2, 2023 /PRNewswire/ — Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, announces preliminary data from a Phase 2 clinical trial of the company’s lead therapeutic candidate, PT-112, in patients with…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.